Prevention Trials

Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.

STUDY10077
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

Study Information
STUDY18956
Hybrid Type 1 Effectiveness Implementation Trial of a Proactive Smoking Cessation Electronic Visit for Scalable Delivery via Primary Care

We will conduct a two-arm clinic-randomized clinical trial (N=672) to examine the effectiveness of a smoking cessation electronic visit (e-visit) vs. treatment as usual (TAU) for smoking cessation across 21 MUSC primary care practices. Main outcomes include: 1) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling), 2) reduction in cigarettes per day, and 3) biochemically verified 7-day PPA at six-month follow-up. We hypothesize that smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU. Secondary outcomes will focus on implementation of the e-visit at the patient, provider, and organizational levels.

Study Information
STUDY19843
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.

Study Information
STUDY21506
Addressing Rural Cancer Disparities via Proactive Smoking Cessation Treatment within Primary Care: A Hybrid Type 1 Effectiveness Implementation Trial of a Scalable Smoking Cessation Electronic Visit

We will conduct a Hybrid Type I effectiveness-implementation trial to comprehensively assess effectiveness of a proactive electronic visit (e-visit) for smoking cessation relative to treatment as usual (TAU) while simultaneously evaluating implementation when delivered across rural primary care settings. In Aim 1, we will conduct a stepped-wedge, cluster-randomized clinical trial (N=288) to examine the effectiveness of the smoking cessation e-visit vs. TAU for smoking cessation across seven rural (Rural-Urban Commuting Area codes 4-10) primary care practices in South Carolina. In Aim 2, we will evaluate e-visit implementation outcomes across rural South Carolina primary care settings at patient, provider, and organizational levels. Main outcomes include: 1) biochemically verified 7-day PPA (point prevalence of abstinence) at six-month follow-up, 2) reduction in cigarettes per day, and 3) evidence-based smoking cessation treatment utilization (medication, psychosocial cessation counseling). We hypothesize that rural smokers randomized to the e-visit condition will have significantly better cessation outcomes relative to TAU.

Study Information
STUDY21923
Impact of Cigarette and E Cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes.

Assess the impact of simulated cigarette and e-cigarette menthol regulations on tobacco use patterns among current menthol smokers. Primary outcomes are a) changes in cigarettes per day (CPD) through Week 6, and secondary outcomes include b) e-cigarette use, and c) ability to remain abstinent. Hypothesis: Assignment to non-menthol cigarettes and assignment to menthol e-liquid will a) reduce cigarettes per day, b) increase e-cigarette use, and c) increase the ability to remain abstinent. We hypothesize an interaction such that effects on tobacco use patterns will be greatest for individuals who receive both non-menthol cigarettes and menthol e-liquid.

Study Information
STUDY22361
Non-cigarette tobacco products as harm reduction tools in smokers who failed to quit with traditional methods

Assess the impact of a switching approach on cigarette smoking behavior. Assess the impact of a switching approach on measures of harm.

Study Information
STUDY23008
A clinical trial of adaptive treatment for early smoking cessation relapse

Aim 1: To determine if, among non-responders to an initial course of FDA-approved smoking cessation medication (either varenicline or combination NRT), it is better to continue use of the same medication or to switch to another. Hypothesis: Among smokers who have not yet responded to one FDA-approved medication, switching to another FDA-approved medication will result in greater success at short-term follow-up, using a clinically relevant and objective measure of success (7-days non-smoking with CO < 6ppm), as compared to medication continuation. Aim 2: To determine if, among non-responders to two courses of FDA-approved medications, it is better to continue use of these same medications or switch to a harm reduction alternative (e-cigarette). Hypothesis: Among smokers who have not yet responded to two courses of FDA-approved pharmacotherapy, switching to e-cigarettes will result in greater abstinence from cigarettes at short-term follow-up. Aim 3: To assess 6-month cessation outcomes among smokers who received only FDA-approved cessation medications (varenicline or combination NRT) vs. a harm reduction alternative (e-cigarette). Hypothesis: Among smokers who have not responded to treatment after two courses of pharmacotherapy, a harm reduction approach will result in higher rates of abstinence at 6 months than another course of pharmacotherapy.

Study Information
STUDY24597
Evaluating an automated tobacco screening and referral intervention to connect home-discharged emergency department patients to the South Carolina Quitline

Describe patient response to an automated tobacco screening and referral intervention designed to connect home discharged emergency department (ED) patients who currently smoked cigarettes to the South Carolina Quitline (SCQL). Over a 20-month reference period, spanning February 2021 to February 2, 2024, we will assess the following seven outcomes: (1) the proportion of home discharged ED patients who screened positive for current smoking; (2) among home discharged ED patients reporting current smoking, the proportion eligible for an automated (IVR interactive voice recognition) call; (3) among home discharged ED patients eligible for automated IVR call, the proportion who were reached by phone; (4) among those reached by phone, the proportion who reported current smoking; (5) among current smokers who answered the automated call, the proportion who accepted a referral to the SCQL; (6) among those who accepted the referral to the SCQL, the proportion who got service from the SCQL; and (7) assess the cost per patient referred to the SCQL.

Study Information
STUDY23716
Evaluating a Tobacco Harm Reduction Strategy Among Clients Enrolled in Substance Use Disorder Treatment

Evaluate if switching to ENDS leads to greater rates of 7-day biologically confirmed point prevalence abstinence (PPA) from cigarette smoking at 12 weeks compared to quitting with NRT among those enrolled in SUD treatment. Evaluate patient, provider, and organizational-level implementation outcomes using mixed methods according to the Proctor framework. Outcomes include: acceptability, appropriateness and feasibility. Quantitative data will be supplemented with in-depth interviews with patients (n=25), providers (n=10), and organizational stakeholders (n=6) to identify barriers and facilitators to implementation

Study Information
STUDY23406
Randomized controlled trial of varenicline to treat tobacco and cannabis co-use

Evaluate rates of 7-day biochemically confirmed point prevalence abstinence (PPA) from cigarettes at the 12-week end of treatment (EOT) visit comparing varenicline + psychosocial intervention to the placebo + psychosocial intervention participants.

Study Information